Menu
Recruiting NCT07566260

Stress and Menstrual Health

No phase Interventional Menstrual Dysfunction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Heat stress, Sleep stress, Exercise stress.
Who it may be relevant to
Registry conditions: Menstrual Dysfunction. Basic parameters: 18 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Influence of Non-energetic Stressors on Human Menstrual Function

Overview

The goal of this experimental study is to determine how stressors that do not directly impact energy state or energy demands (hereafter called "non-energetic stressors") affect reproductive health in pre-menopausal women. It aims to do this by answering the following main questions: Do non-energetic stressors create a stress response? How does the stress response impact sex hormone concentration and thus menstrual dysfunction? If stress caused by non-energetic stressors does impact sex hormone concentration, does it do so primarily at the level of the brain or the level of the ovary? Participants will be enrolled in this study for 6 months. For two of these months, they will undergo a short stress intervention and provide samples to measure hormone concentration and total energy expenditure.

Detailed description

The Reproductive Suppression Model posits that due to the high cost and failure rate of human reproduction, the female body maximizes lifetime reproductive fitness by suppressing reproduction during poor conditions (where likelihood of offspring survival is low) until conditions are more favorable. The hormonal mechanism for this suppression when calories are scarce and the female body is in low energy availability (LEA) has been studied. However, the mechanism for this suppression in the presence of stressors unrelated to low energy availability, but which could still negatively impact offspring survival, is much less clear. The investigators define such stressors, which do not impact energy state or energetic demands, as "non-energetic stressors." Thus, the aim of this study is to determine if non-energetic stressors drive reproductive suppression in humans. The investigators will assess this by testing the impact of a stress intervention on the stress hormones cortisol and norepinephrine, and in turn if the levels of these stress hormones predict the levels of sex hormones associated with the menstrual cycle. Finally, the investigators will assess if changes in stress hormones change total and basal energy expenditure.

Interventions

  • Other Heat stress
    Stress-Heat participants will undergo supervised 40-min sessions in a 70-80˚C sauna
  • Other Sleep stress
    Stress-Sleep participants will be asked to sleep for between 4 and 6 hours per night, with compliance monitored via their activity monitors and self-reported sleep diaries. Participants will be requested to maintain normal wake cycles without midday sleep.
  • Other Exercise stress
    Stress-Exercise participants will come to the Pontzer Lab to complete a one-hour cycling workout on a Lode Corival CPET ergometer/exercise bike at 60-75% predicted maximum heart rate.

Primary outcome measures

  • Total daily energy expenditure (TDEE) [Time frame: Baseline (Month 2), Intervention (Month 4)]
  • Basal metabolic rate (BMR) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
  • Sex hormone concentration (estradiol) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
  • Sex hormone concentration (progesterone) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
Secondary outcome measures (5)
  • Stress hormone concentration (norepinephrine) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
  • Stress hormone concentration (cortisol) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
  • Stress hormone concentration (salivary alpha-amylase) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
  • Sex hormone concentration (luteinizing hormone (LH)) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]
  • Sex hormone concentration (follicle-stimulating hormone (FSH)) [Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)]

Eligibility criteria

Inclusion criteria

  • Adult pre-menopausal females, 18-45 years old
  • Habitually sedentary (less than 60 minutes MVPA/week) for Exercise cohort

Exclusion criteria

  • Individuals on hormonal birth control (oral contraception, injection, implant, or intrauterine device)
  • Individuals with incidence in the last 6 months of childbirth, lactation, pregnancy, or functional hypothalamic amenorrhea (FHA)
  • Individuals with reproductive disorders (e.g. endometriosis, polycystic ovarian syndrome (PCOS))
  • Individuals taking thyroid medications
  • Individuals who have undergone or are undergoing menopause
  • MVPA >60 min/week (for Exercise cohort)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Duke University — Durham

Identifiers

NCT: NCT07566260 · Pro00119656

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗